FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Piekos Brian		 2. Date of Event Requiring Statement (MM/DD/YYYY)
6/9/2020 

 3. Issuer Name and Ticker or Trading Symbol

AMAG PHARMACEUTICALS, INC. [AMAG]
(Last)        (First)        (Middle)

C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Interim CFO /
(Street)

WALTHAM, MA 02451      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 31538 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (2)9/28/2025 Common Stock 9500.0 $39.86 D  
Explanation of Responses:
(1) Includes 18,922 shares of unvested restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of common stock of AMAG Pharmaceuticals, Inc. (the "Issuer").
(2) Grant of stock options pursuant to the Issuer's Third Amended and Restated 2007 Equity Incentive Plan (the "Plan"). The initial option award provided for the vesting of four equal annual installments with the final vesting date which was on September 28, 2019.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Piekos Brian
C/O AMAG PHARMACEUTICALS, INC.
1100 WINTER STREET
WALTHAM, MA 02451

Interim CFO
Signatures
/s/ Carolyn Rucci, attorney-in-fact6/19/2020
**Signature of Reporting PersonDate
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more AMAG Pharmaceuticals Charts.
AMAG Pharmaceuticals (NASDAQ:AMAG)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more AMAG Pharmaceuticals Charts.